News
EC Approves Dyrupeg Biosimilar
Aurobindo announced that the European Commission has granted a marketing authorisation in the European Union for Dyrupeg, a peglyated filgrastim biosimilar, to CuraTeQ Biologics s.r.o.c. a wholly owned subsidiary of Aurobindo
Dyrupeg is intended for the reduction of duration of neutropenia and the incidence of febrile neutropenia in patients with cytotoxic chemotherapy for malignancy except patients with CML and myelodysplastic syndromes.
Condition: Neutropenia
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.